- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Journal: A Case of TAFRO-like Symptoms in a Sj (Pubmed Central) - Aug 31, 2024
The patient was diagnosed with TAFRO-like symptoms occurring with Sj
- |||||||||| Journal: Coexistence of Sj (Pubmed Central) - Aug 31, 2024
Rapid improvement in tubular injury markers and hypobicarbonemia followed potassium supplementation, suggesting that hypokalemia contributed to proximal tubular injury. This case underscores the diagnostic challenge posed by the simultaneous presence of TIN and hypokalemic nephropathy, potentially masking hypokalemic nephropathy in patients with hypokalemic dRTA secondary to SS-TIN.
- |||||||||| Journal: Grp78 regulates NLRP3 inflammasome and participates in Sjogren's syndrome. (Pubmed Central) - Aug 31, 2024
These findings lay the foundation for further investigation into the functionality of SGSCs influenced by ADF and shed light on the cellular and molecular mechanisms by which ADF exerts beneficial actions on salivary gland restoration in SS. FA induces the degradation of Grp78 protein, regulates the NF-?B signaling pathway in SS and inhibited NLRP3 inflammasome activation and reduced the release of inflammatory cytokines to alleviate SS.
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide. (Pubmed Central) - Aug 31, 2024
Herein, we describe the first case of skin-limited LCV induced by once-weekly subcutaneous semaglutide in a 73-year-old man with T2DM, who experienced the complete resolution of the skin lesions shortly after the discontinuation of semaglutide therapy. Future prospective studies, adverse event reporting and post-marketing surveillance will certainly contribute to establishing if LCV represents a less rare than expected side effect of both oral and subcutaneous semaglutide formulations.
- |||||||||| Journal: Novel autoantibodies help diagnose anti-SSA antibody negative Sj (Pubmed Central) - Aug 27, 2024
The findings underscore the importance of recognizing elevated CeD antibodies in patients with SLE, pSS and SSc emphasizing the need for early detection and comprehensive care for gastrointestinal symptoms in these conditions. We present novel autoantibodies in SSA- SjD that have good predictive value for SSA- SjD and FS positivity.
- |||||||||| Journal, Causal relationship: Causal relationship between multiple sclerosis and primary Sj (Pubmed Central) - Aug 27, 2024
Serum BDNF level demonstrated greater predictive advantage for sleep disorder in pSS patients. No significant heterogeneity or horizontal pleiotropy was detected, supporting the reliability of the results.
- |||||||||| Biomarker, Retrospective data, Journal: Salivary Gland Scintigraphy in Sj (Pubmed Central) - Aug 26, 2024
Conclusions SGS is a significant diagnostic tool in the multiparametric evaluation of sicca syndrome, showing strong correlations with histological and immunological markers. Its integration into diagnostic criteria enhances the differentiation between SS and non-Sj
- |||||||||| Journal: Research progress of Hippo pathway effector molecules in rheumatic immune system diseases. (Pubmed Central) - Aug 26, 2024
Effector molecules,such as Yes-associated protein (YAP), transcriptional coactivator with PDZ-binding motif (TAZ), transcriptional enhanced associate domain transcriptional factor (TEAD), monopolar spindle-one binder (MOB1), large tumor suppressor (LATS), can stimulate fibroblast-like synovial cell migration and invasion in rheumatoid arthritis, regulate osteoarthritis disease progression, promote pathological new bone formation in ankylosing spondylitis, sustain submandibular gland development while delaying Sjogren's syndrome progression, mediate alpha-smooth muscle actin in systemic sclerosis, and refine the regulation of target genes associated with pulmonary fibrosis. This article provides an overview of the regulatory mechanisms involving Hippo signaling pathway-related effector molecules in the pathogenesis and progression of rheumatic immune system diseases, to serve as a reference for exploring novel therapeutic targets of rheumatic immune system diseases.
- |||||||||| Biomarker, Journal: miRNAs as potential biomarkers for subclinical atherosclerosis in Sj (Pubmed Central) - Aug 24, 2024
Reduction of specific miRNAs was associated with increased cardiovascular risk, suggesting a potentially protective role for these miRNAs. Furthermore, miR-92a-3p could be helpful for molecular detection of early-stage atherosclerosis and increased cardiovascular risk in SjD.
- |||||||||| Review, Journal: Shrinking lung syndrome in primary Sj (Pubmed Central) - Aug 24, 2024
Treatment includes corticosteroids, immunosuppressants, and respiratory muscle training. This study highlights the importance of considering SLS in the differential diagnosis of patients with pSS and respiratory symptoms.
- |||||||||| Journal: The Mechanism of 540 nm Green Light in Promoting Salivary Secretion. (Pubmed Central) - Aug 23, 2024
Through in-depth bioinformatics analysis and expression verification, ERK1/2 and EphA2 served as potential canonical and noncanonical signals underlying 540 nm green light. Our findings uncovered the novel therapeutic effects of 540 nm green light on xerostomia through regulation on the expression and distribution of TJs.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Efficacy of disease-modifying antirheumatic drugs in primary Sj (Pubmed Central) - Aug 23, 2024
We developed a nomogram to predict RTA occurrence in pSS patients, and it is believed to provide a foundation for early identification and intervention for high-risk pSS patients. AZA, MMF, and RTX have similar effects on pulmonary functions in pSS-ILD and provide disease stabilization.
- |||||||||| Journal: Expressions of type I-III interferons in Sj (Pubmed Central) - Aug 22, 2024
AZA, MMF, and RTX have similar effects on pulmonary functions in pSS-ILD and provide disease stabilization. Serum levels of type I-III IFNs, especially IFN-?, IFN-?, and IFN-?1/IL-29, may serve as a useful biomarker for identification of SS dry eye from non-SS dry eye.
- |||||||||| Journal: Endogenous IL-22 contributes to the pathogenesis of salivary gland dysfunction in the non-obese diabetic model of Sj (Pubmed Central) - Aug 22, 2024
IL-22 neutralization also exerted a protective effect on the salivary gland epithelial cells that express high levels of surface EpCAM and bear the stem cell potential, and IL-22 treatment in vitro hampered the survival/expansion of these salivary gland stem cells, indicating a direct negative impact of IL-22 on these cells. In summary, this study has uncovered a critical pathogenic role of the endogenous IL-22 in the pathogenesis of Sj
- |||||||||| Journal: Can We Differentiate Between Primary Sj (Pubmed Central) - Aug 22, 2024
Although regular and smooth-walled cysts were common in the 2 diseases, irregular and non-smooth-walled cysts were more often associated with iMCD than pSS. Nodules in iMCD tended to be larger and more numerous, and a close positional relationship between nodules and cysts was only observed in iMCD.
- |||||||||| Biomarker, Review, Journal: Roles of TRIM21/Ro52 in connective tissue disease-associated interstitial lung diseases. (Pubmed Central) - Aug 21, 2024
Recent studies indicate that TRIM21 and its autoantibody are involved in the pathogenesis of CTD-ILD and play an important role in diagnosis and prognosis. In this review, we focus on the contribution of TRIM21 in the pathogenesis of CTD-ILD, as well as the potential diagnostic value of its autoantibodies in different types of CTD-ILD for disease progression and potential as a novel therapeutic target.
- |||||||||| Journal, Metastases: Advanced Cystic Lung Disease Secondary to Sj (Pubmed Central) - Aug 20, 2024
In this review, we focus on the contribution of TRIM21 in the pathogenesis of CTD-ILD, as well as the potential diagnostic value of its autoantibodies in different types of CTD-ILD for disease progression and potential as a novel therapeutic target. No abstract available
- |||||||||| Review, Journal: Carpal tunnel syndrome related to rheumatic disease (Review). (Pubmed Central) - Aug 20, 2024
To accurately evaluate patients with RD, a detailed electrophysiological examination should be included in the evaluation process. A diagnostic algorithm should include neuromuscular ultrasound or magnetic resonance imaging for patients with RD.
- |||||||||| hydroxychloroquine / Generic mfg.
Journal: Anogenital Erosive Lichen Sclerosus in a Male With Multiple Autoimmune Conditions. (Pubmed Central) - Aug 19, 2024
Although topical corticosteroids are commonly used, systemic options like hydroxychloroquine may be beneficial in resistant cases, although clear guidelines are lacking. Our case underscores the importance of a multidisciplinary approach in addressing LS and its associated autoimmune conditions.
- |||||||||| Cosentyx (secukinumab) / Novartis, Sotyktu (deucravacitinib) / BMS
Journal: Paradoxical Eczema Associated With Interleukin-17A Inhibitor Use in a Patient With Generalized Pustular Psoriasis Accompanied by Asthma. (Pubmed Central) - Aug 16, 2024
A woman in her 50s with a history of interstitial nephritis attributable to Sjogren's syndrome experienced a flare-up of GPP after discontinuing mycophenolate mofetil and was hospitalized...Her condition improved after switching from secukinumab to deucravacitinib with a temporary increase in the prednisolone level; no recurrence of GPP or PE was observed for 11 months...Our case highlights the need for careful consideration when prescribing IL-17 inhibitors to patients with GPP, particularly those with atopic predispositions, given the potential activation of the Th2 axis and thus severe eczematous reactions. Further research is required to understand the essential nature of PE in patients with GPP and the roles of IL-17A and IL-22 in this context.
- |||||||||| Journal: Autoimmune dysphagia. (Pubmed Central) - Aug 15, 2024
The investigation and management of autoimmune dysphagia requires close collaboration between rheumatologists and otorhinolaryngologists. There is a need for further research to establish standardised guidelines on the assessment and management of autoimmune dysphagia.
- |||||||||| Journal: Chronic Parotitis in Primary Sj (Pubmed Central) - Aug 14, 2024
Nevertheless, hemodialysis remained necessary in our case, and whether or not aliskiren can restore the renal function is unclear. No abstract available
- |||||||||| Journal: Exploring the crosstalk molecular mechanisms between IgA nephropathy and Sj (Pubmed Central) - Aug 13, 2024
In the immune cell analysis, the effector memory CD8 T and T follicular helper cells were significantly activated, and the corresponding proportions showed positively correlations with the expressions of the 5 hub genes in the two autoimmune diseases. Together, our data identified the crosstalk genes, molecular pathways, and immune cells underlying the IgAN and SS, which provides valuable insights into the intricate mechanisms of these diseases and offers potential intervention targets.
- |||||||||| Journal: Primary Localized Labial Amyloidosis Associated with Sj (Pubmed Central) - Aug 13, 2024
Together, our data identified the crosstalk genes, molecular pathways, and immune cells underlying the IgAN and SS, which provides valuable insights into the intricate mechanisms of these diseases and offers potential intervention targets. No abstract available
- |||||||||| Nucala (mepolizumab) / GSK, Rituxan (rituximab) / Roche
Journal: The Puzzling Coexistence of Eosinophilic Pneumonia With Sjogren's Syndrome: A Diagnostic Dilemma. (Pubmed Central) - Aug 13, 2024
We present a case where a patient with no significant pulmonary nor autoimmune medical history presents with acute hypoxic respiratory failure and a dry cough that's made worse when conversing. She gets diagnosed with eosinophilic pneumonia after bronchoalveolar lavage (BAL) showed 70% eosinophils while also having labs highly suggestive of primary Sjogren's syndrome (pSS) with an anti-SSA titer of 111.3 U/mL and anti-SSA 52 kD Ab, immunoglobulin (Ig)G >200 U. The initial treatment plan was to start rituximab to target
|
